Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Saved in:
| Title: | Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer. |
|---|---|
| Authors: | Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. sarahl_sammons@dfci.harvard.edu., Yardley DA; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Sharma P; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA., Gadi VK; Division of Hematology and Oncology, University of Illinois Cancer Center, Chicago, IL, USA., Pegram M; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Hu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Fasching PA; Gynecology and Obstetrics Translational Medicine, University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. |
| Source: | Oncology and therapy [Oncol Ther] 2026 Mar; Vol. 14 (1), pp. 19-25. Date of Electronic Publication: 2025 Nov 14. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101677510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2366-1089 (Electronic) Linking ISSN: 23661089 NLM ISO Abbreviation: Oncol Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
